These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36406430)

  • 1. Resistance to aztreonam-avibactam due to CTX-M-15 in the presence of penicillin-binding protein 3 with extra amino acids in
    Ma K; Zong Z
    Front Microbiol; 2022; 13():1047109. PubMed ID: 36406430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of aztreonam/avibactam against metallo-β-lactamase-producing Enterobacterales from the UK: Impact of penicillin-binding protein-3 inserts and CMY-42 β-lactamase in Escherichia coli.
    Livermore DM; Mushtaq S; Vickers A; Woodford N
    Int J Antimicrob Agents; 2023 May; 61(5):106776. PubMed ID: 36893810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aztreonam-avibactam may not replace ceftazidime/avibactam: the case of KPC-21 carbapenemase and penicillin-binding protein 3 with four extra amino acids.
    Ma K; Feng Y; Zong Z
    Int J Antimicrob Agents; 2022 Sep; 60(3):106642. PubMed ID: 35872296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced susceptibility to aztreonam-avibactam conferred by acquired AmpC-type β-lactamases in PBP3-modified Escherichia coli.
    Helsens N; Sadek M; Le Terrier C; Poirel L; Nordmann P
    Eur J Clin Microbiol Infect Dis; 2024 Feb; ():. PubMed ID: 38319508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Struggle To Survive: the Choir of Target Alteration, Hydrolyzing Enzyme, and Plasmid Expression as a Novel Aztreonam-Avibactam Resistance Mechanism.
    Ma K; Feng Y; McNally A; Zong Z
    mSystems; 2020 Nov; 5(6):. PubMed ID: 33144312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3.
    Alm RA; Johnstone MR; Lahiri SD
    J Antimicrob Chemother; 2015 May; 70(5):1420-8. PubMed ID: 25634992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends of β-Lactamase Occurrence Among
    Castanheira M; Kimbrough JH; DeVries S; Mendes RE; Sader HS
    Open Forum Infect Dis; 2023 Feb; 10(2):ofad038. PubMed ID: 36776778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Occurrence of High Levels of Cefiderocol Resistance in Carbapenem-Resistant Escherichia coli before Its Approval in China: a Report from China CRE-Network.
    Wang Q; Jin L; Sun S; Yin Y; Wang R; Chen F; Wang X; Zhang Y; Hou J; Zhang Y; Zhang Z; Luo L; Guo Z; Li Z; Lin X; Bi L; Wang H
    Microbiol Spectr; 2022 Jun; 10(3):e0267021. PubMed ID: 35481835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019.
    Mendes RE; Doyle TB; Streit JM; Arhin FF; Sader HS; Castanheira M
    J Antimicrob Chemother; 2021 Oct; 76(11):2833-2838. PubMed ID: 34436603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates.
    Le Terrier C; Nordmann P; Sadek M; Poirel L
    J Antimicrob Chemother; 2023 May; 78(5):1191-1194. PubMed ID: 36921067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic Features Leading to Reduced Susceptibility to Aztreonam-Avibactam among Metallo-β-Lactamase-Producing Escherichia coli Isolates.
    Sadek M; Juhas M; Poirel L; Nordmann P
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32988825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of clinical isolates of Enterobacterales with elevated MIC values for aztreonam-avibactam from the INFORM global surveillance study, 2012-2017.
    Estabrook M; Kazmierczak KM; Wise M; Arhin FF; Stone GG; Sahm DF
    J Glob Antimicrob Resist; 2021 Mar; 24():316-320. PubMed ID: 33524556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Enterobacteriaceae Isolates Producing Extended-Spectrum β-Lactamases from U.S. Hospitals.
    Castanheira M; Doyle TB; Mendes RE; Sader HS
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31085510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Searching for the Optimal Treatment for Metallo- and Serine-β-Lactamase Producing Enterobacteriaceae: Aztreonam in Combination with Ceftazidime-avibactam or Meropenem-vaborbactam.
    Biagi M; Wu T; Lee M; Patel S; Butler D; Wenzler E
    Antimicrob Agents Chemother; 2019 Sep; 63(12):. PubMed ID: 31570403
    [No Abstract]   [Full Text] [Related]  

  • 15.
    Cervino I; Gonzalez D; Nastro M; Vega J; Reyes AP; Buriano G; Vay C; Famiglietti A; Rodriguez CH
    J Med Microbiol; 2021 Oct; 70(10):. PubMed ID: 34605763
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Kazmierczak KM; Bradford PA; Stone GG; de Jonge BLM; Sahm DF
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249690
    [No Abstract]   [Full Text] [Related]  

  • 17. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
    Aktaş Z; Kayacan C; Oncul O
    Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains.
    Castanheira M; Mills JC; Costello SE; Jones RN; Sader HS
    Antimicrob Agents Chemother; 2015; 59(6):3509-17. PubMed ID: 25845862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition by Avibactam and Clavulanate of the β-Lactamases KPC-2 and CTX-M-15 Harboring the Substitution N
    Ourghanlian C; Soroka D; Arthur M
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of cefepime/zidebactam against MDR Escherichia coli isolates harbouring a novel mechanism of resistance based on four-amino-acid inserts in PBP3.
    Bhagwat SS; Hariharan P; Joshi PR; Palwe SR; Shrivastava R; Patel MV; Devanga Ragupathi NK; Bakthavatchalam YD; Ramesh MS; Soman R; Veeraraghavan B
    J Antimicrob Chemother; 2020 Dec; 75(12):3563-3567. PubMed ID: 32772098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.